Pharma
Deals

A muddled deal has scarred Aurobindo Pharma. Regaining investor confidence won’t be easy.

A muddled deal has scarred Aurobindo Pharma. Regaining investor confidence won’t be easy.

Courtesy of Aurobindo Pharma

Synopsis

Aurobindo Pharma has built a strong and diverse product pipeline to drive future growth. But corporate-governance issues and promoters’ history will be an overhang for the stock and are likely to have a bearing on investors’ perception of the second-largest pharma company in India in terms of revenue.

By
9 mins read, Last Updated:
A deal done and undone in a jiffy has left Aurobindo Pharma in disarray. Not only has its stock been among the worst performers, the company’s reputation has also taken a beating. On August 12, Aurobindo Pharma announced its decision to acquire 51% stake in Cronus Pharma Specialities India Pvt Ltd, a company that makes veterinary pharma products, for a cash consideration of INR420 crore. On the same day, Aurobindo Pharma also reported

To Read the Full Story, Become an ET Prime Member

Access the exclusive Economic Times stories, Editorial and Expert opinion

Subscribe Now

Monsoon Offer

Get flat 20% off

on ETPrime membership

Membership Benefits

Access the exclusive Economic Times

Stories, Editorial & Expert opinion

Complete Access with ET Prime

Experience your Economic Times newspaper, The way you've always liked!

Get to know where the market gurus invest & grow your portfolio.

Stock Report Plus

In-depth stock analysis for 4000+ companies

Stock Analyzer

Instant stock analysis based on Solvency, Profitability, Growth, Valuation, Momentum, Risk & More.

Now Available with ET Prime

Manage your money efficiently with this weekly guide.

Clean experience

with minimal ads

Easy & distraction-free reading with 90% less ads

Sharp Insight-rich,

In-depth stories across 20+ sectors

1500+ Exclusive stories & analysis across sectors to help you stay informed

Get One Year Times Prime Subscription worth ₹1199 for free

Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-

Enjoy unlimited access to breaking news and thought provoking stories from all around the world.

Get One Year Docubay Subscription worth ₹999 for free

Stream award-winning international documentaries from more than 100 countries.

Offers By Our Partners

Exclusively for ET Prime Members

Members Love Us

The stalwarts of the industry trust ET Prime for insightful analysis & unbiased thought pieces

Gift a story

Your membership includes Story Gifting Credits. Now gift exclusive stories to your friends & peers.

Comment & Engage

with ET Prime community

Communicate & build a connection with great minds of the industry

A trusted team of

Journalists & Analysts

Unbiased perspective & detailed reporting by our team of journalists who have in-depth knowledge and years of experience